Trial Profile

A Phase I/II Study of Foretinib in Combination with Lapatinib in Patients with Human Epidermal Growth Factor Receptor 2(HER2)Over-Expressing Metastatic Breast Cancer.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Foretinib (Primary) ; Lapatinib (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Adverse reactions

Most Recent Events

15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
07 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Sep 2014.
21 Sep 2013 Lead centres updated as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com